How to Get Addyi in Washington State

What Is Addyi and Why Does Washington Access Matter?

Flibanserin 100 mg (Addyi) is the only FDA-approved non-hormonal oral medication for generalized acquired HSDD in premenopausal women. The FDA granted approval on August 18, 2015, based on data from the BEGONIA trial and two other Phase III studies showing statistically significant improvements in satisfying sexual events (SSEs) and desire scores compared to placebo [1][2]. Washington State has a telehealth-friendly prescribing environment and a Medicaid program that covers Addyi when prior authorization criteria are met, which means most premenopausal women in the state have a viable pathway to the drug without traveling to a specialist.

HSDD affects an estimated 8 to 10 percent of adult women in the United States, according to a prevalence analysis published in the Journal of Sexual Medicine [3]. Despite that prevalence, access has historically been limited by prescriber unfamiliarity with the FDA Risk Evaluation and Mitigation Strategy (REMS) program that gates who can legally write the prescription. Washington's telehealth infrastructure lowers that barrier considerably.

The BEGONIA trial (N=1,223) demonstrated that flibanserin 100 mg nightly produced a mean increase of 0.6 SSEs per 28 days versus 0.2 for placebo (P<0.001) and a statistically significant reduction on the Female Sexual Distress Scale-Revised (FSDS-R) [1]. Those modest but real effect sizes are the clinical basis for the drug's continued use.

Washington State Telehealth Rules for Flibanserin

Washington permits synchronous audio-video telehealth visits for controlled and non-controlled prescriptions, and flibanserin is not a controlled substance. Under RCW 70.41.020 and the Washington Health Care Authority telehealth policy updated in 2023, a licensed Washington provider may conduct an initial evaluation by video and issue a new prescription without a prior in-person encounter, provided the visit meets the same standard of care as an in-person encounter [4].

Telehealth prescribing is fully allowed. Addyi does not require a pelvic exam before prescribing, so a structured video interview covering the DSM-5 criteria for HSDD, medication history, alcohol use, and liver function review is sufficient for most patients.

Several national telehealth platforms hold Washington State licenses and offer REMS-certified providers. A consultation typically takes 20 to 40 minutes. The provider reviews:

• Symptom duration (must be at least 6 months for a HSDD diagnosis per DSM-5 criteria) [5]
• Current medications, with special attention to CYP3A4 inhibitors (fluconazole, ketoconazole, certain SSRIs) that are contraindicated with flibanserin [2]
• Alcohol consumption, because concurrent alcohol use raises the risk of severe hypotension and syncope and is listed as a contraindication in the FDA label [2]
• Hepatic status, since moderate-to-severe hepatic impairment is also a contraindication [2]

After the video visit, the certified provider enters the prescription into the REMS system and routes it to a pharmacy of the patient's choice.

The REMS Program: What It Requires in Practice

The Addyi REMS program, administered by Sprout Pharmaceuticals under FDA oversight, requires three things: the prescriber must be certified, the pharmacy that dispenses must be certified, and the patient must receive a medication guide acknowledging the alcohol and CNS-depressant interaction risks [2].

Prescribers complete a short online training module (roughly 30 minutes) and attest to understanding the risk profile. The program does not require the prescriber to observe the patient abstain from alcohol in clinic. Certification is free and remains active as long as the prescriber stays current with any FDA-required updates.

Pharmacies, including mail-order pharmacies that ship into Washington, must also hold REMS certification. Patients can verify whether their Washington pharmacy is REMS-certified through the Addyi REMS website or by asking the pharmacist directly before transferring a prescription.

The FDA's 2019 label revision removed the requirement for prescriber co-dispensing counseling on alcohol abstinence from the label's strictest language, but the counseling obligation itself remains in the REMS materials [2].

Who Can Prescribe Addyi in Washington?

Any licensed Washington prescriber who completes REMS certification may write a flibanserin prescription. This includes:

MDs and DOs. Ob-gyns, family medicine physicians, and internal medicine physicians are the most common Addyi prescribers nationally. A 2021 analysis in Women's Health Issues found ob-gyns accounted for approximately 42 percent of all flibanserin prescriptions in the United States [6].

Nurse practitioners (ARNPs). Washington grants full practice authority to advanced registered nurse practitioners under RCW 18.79. An ARNP with independent prescriptive authority needs no physician co-signature and may complete REMS certification independently.

Physician assistants (PAs). Washington PAs practice under RCW 18.71A and may prescribe independently in most settings after 2023 scope-of-practice updates. A PA who is REMS-certified can legally prescribe flibanserin without a collaborating physician's countersignature for most practice settings.

CNMs. Certified nurse-midwives licensed in Washington may also prescribe flibanserin for premenopausal patients within their scope.

The prescriber type does not affect the REMS certification process. Each provider category goes through the same online module.

Labs and Testing Before Starting Addyi

No mandatory laboratory tests are required by the FDA label before initiating flibanserin. The contraindications are clinical, not lab-gated.

A prescriber should review liver function if there is any history of hepatic disease, heavy alcohol use, or elevated liver enzymes on recent bloodwork. If no liver disease history exists and the patient reports minimal alcohol use, no liver panel is strictly required before the first prescription [2].

Some Washington telehealth platforms order a basic metabolic panel or liver function tests (AST, ALT, total bilirubin) as a precautionary step in their own clinical protocols, particularly when a patient reports any of the following: regular alcohol consumption above 3 drinks per week, a history of hepatitis, or concurrent use of medications with hepatotoxic potential. This is a clinical judgment call, not an FDA requirement.

A complete medication reconciliation is the single most important pre-prescribing step. CYP3A4 inhibitors, including azole antifungals (fluconazole, itraconazole, ketoconazole), several macrolide antibiotics (clarithromycin), and HIV protease inhibitors, are contraindicated because they can raise flibanserin plasma concentrations by 4- to 7-fold and sharply increase hypotension risk [2][7].

HealthRX Pre-Prescribing Checklist for Flibanserin in Washington

| Step | What to Assess | Pass Criterion | |------|---------------|----------------| | 1 | DSM-5 HSDD criteria | Symptoms present for ≥ 6 months, not attributable to another condition or drug | | 2 | Alcohol use | Average ≤ 3 drinks per week; patient agrees to complete abstinence while taking Addyi | | 3 | Hepatic history | No moderate-to-severe hepatic impairment | | 4 | Medication reconciliation | No CYP3A4 strong inhibitors; no CNS depressants at doses producing additive sedation | | 5 | Menopausal status | Pre-menopausal (FSH, LH, or clinical history if uncertain) | | 6 | Relationship/contextual factors | Distress not fully explained by relationship discord, another psychiatric diagnosis, or substance use |

Washington Medicaid Coverage and Prior Authorization

Washington's Apple Health (Medicaid) program covers flibanserin for premenopausal women with a diagnosis of HSDD (ICD-10 F52.0), but prior authorization is required.

Washington Medicaid PA criteria for Addyi typically require:

1. A confirmed diagnosis of generalized acquired HSDD documented in the clinical record.
2. Evidence that the low desire causes marked distress or interpersonal difficulty, consistent with DSM-5 criterion C for HSDD [5].
3. Verification of premenopausal status.
4. Confirmation that no contraindicated medications are active on the patient's medication list.
5. Documentation that the patient has been counseled on the alcohol interaction and has agreed to restrict alcohol use.

Some Washington Medicaid managed care organizations (MCOs) add a step-therapy requirement. A few MCOs ask for documentation that a brief course of sexual counseling or psychotherapy was attempted or offered, though a refusal of counseling is generally sufficient documentation. Prescribers should submit PA requests with chart notes from the qualifying visit and, when available, a completed FSDS-R score showing clinically significant distress [8].

Commercial insurance coverage varies. Many Washington commercial plans cover Addyi when a PA is submitted with the same documentation set. A 2020 analysis of prescription drug coverage databases found that only 27 percent of commercial plans covered flibanserin without PA, while 48 percent covered it with PA and 25 percent excluded it entirely [9]. Sprout Pharmaceuticals offers a savings card program that may reduce out-of-pocket costs to as low as $99 per month for commercially insured patients who are ineligible for Medicaid.

503A Compounding Pharmacies in Washington

Licensed 503A compounding pharmacies in Washington may compound flibanserin for individual patients with a valid prescription. 503A pharmacies compound on a patient-specific basis, meaning each preparation requires a prescription from a REMS-certified prescriber for that specific patient [10].

Compounded flibanserin is not FDA-approved and does not carry the brand-name bioavailability or stability data that the 100 mg Addyi tablet carries. Some patients pursue compounding when brand-name Addyi is cost-prohibitive or when a prescriber wants to titrate to a dose below 100 mg to manage side effects such as somnolence or dizziness, which occurred in 11.4 percent of participants in clinical trials [1][2].

Washington 503A pharmacies must be licensed by the Washington State Pharmacy Quality Assurance Commission (PQAC) and must comply with USP 795 standards for non-sterile compounding. Patients should confirm their compounding pharmacy holds an active Washington PQAC license before transferring a prescription.

Mail-order compounding pharmacies licensed in other states may ship into Washington, provided they hold a Washington non-resident pharmacy license issued by PQAC. The prescriber's REMS certification applies regardless of whether the dispensing pharmacy fills the brand-name product or a compounded preparation, because the REMS obligation attaches to the prescriber at the point of writing the prescription.

How Long Does It Take to Get Addyi in Washington?

The timeline from first contact to first dose depends on your path.

Telehealth route. Most Washington telehealth platforms offering flibanserin can schedule a new-patient visit within 24 to 72 hours. Once the provider completes the REMS certification (if not already certified) and transmits the prescription electronically, a REMS-certified mail-order pharmacy typically ships within 1 to 2 business days. Total time from booking to delivery: 3 to 7 days for the majority of patients.

In-person route. A new-patient appointment with a Washington ob-gyn or primary care physician runs 1 to 4 weeks on average. If prior authorization is needed (Medicaid or certain commercial plans), allow an additional 3 to 14 business days depending on the MCO's turnaround time. Washington Medicaid MCOs are required under WAC 182-501-0165 to respond to standard PA requests within 14 calendar days.

Compounding route. A 503A pharmacy typically compounds and ships within 3 to 5 business days after receiving a valid prescription. No REMS pharmacy certification is required of the 503A compounder for the prescription to be valid, but the prescriber must still be REMS-certified [10].

Transferring an existing Addyi prescription from another state to a Washington pharmacy is straightforward. The receiving Washington pharmacy must be REMS-certified. Electronic transfer or a new e-prescription to the Washington pharmacy from your original REMS-certified prescriber are both acceptable. If you are also transferring your care to a new Washington provider, that provider must complete their own REMS certification before writing a new prescription.

Side-Effect Profile and Monitoring

Flibanserin's most clinically relevant adverse effects are somnolence (reported in 11.4 percent of trial participants), dizziness (reported in 11.2 percent), and nausea (reported in 10.4 percent), all based on pooled Phase III data reviewed in the FDA medical officer report [2]. These effects are largely dose-time-dependent. Taking the 100 mg dose at bedtime rather than earlier in the evening reduces next-morning sedation in most patients.

Severe hypotension and syncope are the events driving the REMS program. In a dedicated drug-interaction trial cited in the FDA label, healthy pre-menopausal women who consumed 0.4 g/kg of alcohol (approximately 2 standard drinks) within 2 hours of taking flibanserin had a 6-fold increase in hypotensive events and a 4-fold increase in syncope compared to flibanserin alone [2].

Routine follow-up at 4 and 8 weeks after starting flibanserin is appropriate to assess:

• Symptom response (a 0.5-unit change on the FSDS-R is considered the minimum clinically important difference) [8]
• Tolerability, specifically somnolence and dizziness
• Ongoing alcohol and drug-interaction review

The FDA label states the drug should be discontinued if no improvement in desire or distress is apparent after 8 weeks at 100 mg nightly [2].

Transferring an Existing Prescription to Washington

Patients who move to Washington from another state or who want to consolidate care with a Washington provider can transfer their flibanserin prescription with minimal friction.

The simplest approach is to ask your current out-of-state prescriber to send an electronic prescription to a REMS-certified Washington or national mail-order pharmacy. Most e-prescribing platforms support cross-state electronic transmission. The prescription must still come from a REMS-certified prescriber; that certification does not expire unless the prescriber voluntarily withdraws or Sprout Pharmaceuticals revokes it.

If your prescriber is not licensed in Washington, they cannot legally continue to prescribe for a Washington resident under RCW 18.71.021, which requires a valid Washington license for ongoing prescriptive relationships with Washington patients. In that case, establish care with a Washington-licensed, REMS-certified provider. A telehealth intake visit is sufficient to generate a new prescription.

Some Washington pharmacies may attempt to process an out-of-state paper prescription for Addyi. Paper prescriptions are not prohibited, but the dispensing pharmacy must still be REMS-certified, and many non-certified retail pharmacies will reject the prescription at the counter. Confirm REMS certification before presenting any prescription.

Cost and Savings Options in Washington

Brand-name Addyi (flibanserin 100 mg, 30-tablet supply) has a wholesale acquisition cost of approximately $835 per month as of 2025. Out-of-pocket cost varies sharply by insurance.

• Washington Apple Health (Medicaid). Covered with PA. Co-pay is typically $0 to $3 for fee-for-service enrollees.
• Commercial insurance with PA approval. Co-pays range from $30 to $150 per month depending on plan tier.
• Cash-pay with Sprout savings card. Commercially insured patients may pay as little as $99 per month. Uninsured patients are not eligible for the manufacturer card but may qualify for patient assistance through Sprout's access program.
• Compounded flibanserin. 503A pharmacies in Washington typically charge $60 to $180 per month for compounded flibanserin, though price varies widely by pharmacy and formulation.

A published 2022 cost-effectiveness analysis in PharmacoEconomics estimated that flibanserin's incremental cost-effectiveness ratio at the $835 monthly price point exceeds standard willingness-to-pay thresholds in the United States, which is why insurance PA requirements and prior counseling mandates remain common [11].

Clinical Evidence Summary

The three key Phase III trials that supported FDA approval enrolled a combined 2,848 premenopausal women with HSDD. Pooled results showed a mean increase of 0.5 to 1.0 SSEs per 28 days versus placebo across trials, a statistically significant decrease in FSDS-R distress scores, and a statistically significant increase on the Female Sexual Function Index desire domain [1][2]. The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin No. 213 states: "Flibanserin may be considered for premenopausal women with generalized acquired HSDD who are not taking CYP3A4 inhibitors and who do not use alcohol regularly" [12].

The International Society for the Study of Women's Sexual Health (ISSWSH) process-of-care pathway published in the Journal of Sexual Medicine in 2019 lists flibanserin as a first-line pharmacotherapy option for premenopausal women after a structured biopsychosocial evaluation confirms the HSDD diagnosis [13].

Effect sizes are moderate, not dramatic. The number needed to treat (NNT) for one additional SSE per 28 days over placebo is approximately 8, based on BEGONIA trial data [1]. Patients who understand this expectation tend to report higher satisfaction with the drug than those expecting a dramatic response.